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Abstract
Introduction: Metabolic syndrome predicts the development of CVD. Lipid abnormalities probably have an important influence on the 
increase of cardiovascular death risk. The SCORE chart includes only total cholesterol level, which may be inadequate. The aim of our 
study was to evaluate the lipid profile in patients with metabolic syndrome according to the cardiovascular risk calculated on the basis 
of the SCORE chart. 
Material and methods: The study participants comprised 974 patients with metabolic syndrome. The 10-year death risk of cardiovascular 
disease was calculated on the basis of SCORE chart in all patients. The study group was divided in three subgroups depending on the 
risk level calculated by SCORE scale. 
Results: There was a significantly higher level of LDL-C fraction in the subgroup of very high CV risk in comparison to the group of 
medium and high CV risk. The level of non-HDL-C was also significantly higher in the group with SCORE ≥ 10 compared to the remain-
ing subgroups of medium and high CV risk. 
Conclusions. Increased CV risk in this group of patients may be associated not only with higher TC level, but also the other lipid fractions. 
The assessment of the CV risk on the basis of the SCORE chart, which includes only TC level, may be inadequate. A modification of the 
SCORE chart for the European population should be considered (inclusion of LDL-C level, or in selected cases non-HDL-C level instead 
of TC level). (Endokrynol Pol 2016; 67 (3): 265–270)
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Streszczenie
Wstęp: Zespół metaboliczny poprzedza rozwój choroby sercowo-naczyniowej. Ważny wpływ na zwiększenie ryzyka sercowo-naczy-
niowego mają prawdopodobnie zaburzenia gospodarki lipidowej. W skali SCORE ujęto jedynie poziom cholesterolu całkowitego, który 
może być nieadekwatny. 
Celem naszej pracy była ocena profile lipidowego u pacjentów z zespołem metabolicznym w zależności od obliczonego na podstawie 
skali SCORE ryzyka sercowo-naczyniowego. 
Materiał i metody: Do badania włączono 974 pacjentów z zespołem metabolicznym. Dziesięcioletnie ryzyko nagłego zgonu z przyczyn 
sercowo-naczyniowych obliczono na podstawie skali SCORE chart u wszystkich pacjentów. Badaną grupę podzielono na 3 podgrupy 
w zależności od poziomu ryzyka obliczonego za pomocą skali SCORE. 
Wyniki: Stwierdzono istotnie wyższe stężenie cholesterolu frakcji LDL w podgrupie pacjentów z bardzo wysokim ryzykiem sercowo-
-naczyniowym w porównaniu z podgrup wysokiego i średniego ryzyka sercowo-naczyniowego. Stężenie cholesterolu frakcji non-HDL 
był również istotnie wyższy w podgrupie bardzo wysokiego ryzyka sercowo-naczyniowego. 
Wnioski: Zwiększone ryzyko sercowo-naczyniowe w grupie pacjentów z zespołem metabolicznym może być związane nie tylko z wy-
sokim stężeniem cholesterolu całkowitego, ale również z innymi frakcjami lipidowymi. 
Ocena ryzyka sercowo-naczyniowego na podstawie skali SCORE, która zawiera jedynie stężenie cholesterolu całkowitego, może być 
nieodpowiednia. Trzeba rozważyć modyfikacje skali SCORE w populacji Europejczyków (włączenie do oceny cholesterolu frakcji LDL, 
non-HDL, zamiast cholesterolu całkowitego). (Endokrynol Pol 2016; 67 (3): 265–270)
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Marcin Gierach M.D., Department of Endocrinology and Diabetology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University 
in Toruń, M. Skłodowskiej-Curie Str. 9, 85–094 Bydgoszcz, Poland, phone: +4852 585 42 40, fax: +4852 585 4241, e-mail: marcin_gierach@wp.pl
266
PR
A
C
E 
O
RY
G
IN
A
LN
E
Evaluation of lipid profiles in patients with MetS  Marcin Gierach et al.
Introduction
Cardiovascular diseases (CVD) are a significant cause of 
death in Europe and worldwide [1–4]. In Poland CVD 
caused 46.0% of all deaths in 2010 [5]. In the European 
Union, to estimate cardiovascular disease risk and to 
apply primary cardiovascular (CV) prevention, the 
SCORE chart is used. The SCORE chart evaluates the 
10-year death risk of CVD and is based on the following 
risk factors: gender, age, systolic blood pressure [SBP], 
total cholesterol [TC], and smoking.
Metabolic syndrome (MetS) comprises a constella-
tion of CV risk factors that include abdominal obesity, 
insulin resistance, glucose intolerance, elevated blood 
pressure or antihypertensive drug treatment, low lev-
els of high-density lipoprotein (HDL-C) cholesterol, 
and elevated triglyceride (TG) levels [6–10]. Abundant 
evidence shows that MetS predicts the development 
of CVD [11–13].
Lipid abnormalities probably have an important 
influence on the increase in CV death risk. Also, in 
patients with MetS, lipid disorders have an unques-
tionable impact on the increase of the risk of CV death.
It is worth mentioning that according the SCORE 
chart, to assess CV risk only the total cholesterol level 
is taken into consideration. But sometimes TC may be 
misleading, for example in patients with MetS, who of-
ten have low HDL-C levels. Calculation of low-density 
lipoprotein cholesterol (LDL-C) is also very important 
because it is still widely used and it is the first lipid 
target of therapy (IA class) according to the guidelines 
for the management of dyslipidaemias of the European 
Atherosclerosis Society and the European Society of 
Cardiology (ESC/EAS) [14, 15]. In patients with multiple 
CV risk factors LDL-C is suggested as being essential 
to effectively manage the overall risk [16, 17]. Thus, for 
an adequate risk analysis, at least HDL-C and LDL-C 
should be analysed [14]. 
Therefore, the aim of our study was to evaluate 
the lipid profile in patients with MetS according to 
the CV risk calculated on the basis of the SCORE 
chart. 
Material and methods
The described study was conducted in a two-centre 
(University Hospital No. 1 in Bydgoszcz, District Hospi-
tal in Wąbrzeźno, Poland) screening study of 36 months 
duration (2011–2014 years). The study participants 
comprised 974 patients, average aged 58.3 years (± SD 
11,9; min — 42; max — 71), with MetS diagnosed accord-
ing to the 2005 IDF (International Diabetes Federation) 
criteria (meeting at least three criteria). The criteria are 
presented in Table I.
Anthropometric measurements (height, weight, and 
waist circumference — WC) were taken in all subjects. 
Body mass index (BMI) was calculated according to the 
formula: body weight (in kilograms) divided by the 
square of body height (in metres). WC was measured 
at the point midway between the last rib and the iliac 
crest. Demographic factors (age, gender, obesity) were 
determined. Blood pressure was measured by auto-
matic blood pressure monitor. The measurements were 
performed with the participant in a seated position, on 
the right and left upper arm, after at least 10 minutes 
of rest and 5-minute intervals. Fasting total plasma 
cholesterol, triglycerides, and high-density lipoprotein 
cholesterol were determined in all patients. Low-
density lipoprotein cholesterol was calculated using the 
Friedewald formula. The non-high-density lipoprotein 
cholesterol (non-HDL-C) values were obtained finding 
the difference between TC and HDL-C. In patients with 
waist circumference > 80 cm in females and > 94 cm 
in males or with fasting glucose level > 100 mg/dL the 
oral glucose tolerance test (OGTT) was performed. 
Glomerular Filtration Rate (GFR) [mL/min/1.73 m2] was 
measured by means of MDRD formula.
The 10-year death risk of CVD was calculated on 
the basis of SCORE chart in all patients. The study 
group was divided in three subgroups depending on 
the risk level calculated by SCORE scale: patients with 
medium (1–4%), high (5–9%), and very high CV risk 
(≥ 10%). Additionally, patients with diabetes mellitus 
type 1 and 2 without CV risk factor or target organ 
damage, or moderate chronic kidney disease (GFR 
30–59 mL/min/1.73m2) or markedly elevated single 
CV risk factor (e.g. familial dyslipidaemia or severe 
hypertension) were included ad hoc into the group of 
high CV risk. Whereas, to the group of very high CV 
risk (≥ 10%), additionally, patients with DM type 1 or 
type 2 with one or more CV risk factor/s and/or target 
organ damage, documented CVD (including coronary 
disease, peripheral artery disease or stroke), or severe 
Table I. IDF criteria of metabolic syndrome
Tabela I. Kryteria rozpoznania zespołu metabolicznego w IDF
Abdominal obesity [cm] F ≥ 80 or M ≥ 94
Arterial hypertension (HT) [mm Hg] ≥ 130/85 or treated for arterial 
hypertension
Triglycerides (TG) [mg/dL] ≥ 150 [1.7 mmol/L] or treated for 
dyslipidaemia 
HDL-C [mg/dL] < 50 [1.3 mmol/L] in women  
and < 40 [1.0 mmol/L] in men
Fasting glycaemia [mg/dL] ≥ 100 [5.6 mmol/L] or treated  
for diabetes
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chronic kidney disease (GFR < 30 mL/min/1.73 m2) 
were included.
Exclusion criteria were as follows: (1) a history of 
heart surgery or other cardiovascular interventions, 
(2) congenital defects of the heart, (3) cardiac rhythm 
disorders, (4) pregnancy, (5) electrolyte disorders, (6) 
inflammation, (7) anaemia, (8) prostate disease, (9) 
Cushing’s syndrome, (10) thyroid disorders. 
The results of the study were analysed statisti-
cally. Quantitative data were presented as arithmetic 
means with standard deviations. In order to verify 
the conformity of variable distribution with normal 
distribution, the Shapiro–Wilk test was used. For the 
comparison of the subgroups the Kruskal-Wallis test 
was used. Additionally, a nonparametric version of the 
Student’s t-test for independent variables was used. All 
hypotheses were verified at p  =  0.05. Values of p < 0.05 
were considered as statistically significant. All statistical 
analyses were performed using Statistica 10.0 software 
(Statsoft Poland, Bydgoszcz). 
The study protocol was approved by the Bioethics 
Committee of Ludwig Rydygier Collegium Medicum in 
Bydgoszcz, Nicolaus Copernicus University in Toruń. 
All subjects gave their informed consent for participa-
tion in the study.
Results
The study group consisted of 974 patients [574 females 
(58.9%) and 400 males (41.1%)] of mean age 58.3 ± 11.9 
years (min 42; max 71 years). The mean value of BMI 
was 30.7 ± 5.5 kg/m2, mean WC was 107.9 ± 13.1 cm, 
and mean SBP was 144.7 ± 20.1 mm Hg. Mean values 
of lipid fractions were as follows: LDL-C — 113.9 ± 
± 41.2 mg/dL; TG — 148.0 ± 89.0 mg/dL, HDL-C — 42.6 ± 
± 11.9 mg/dL and non-HDL-C — 142.5 ± 46.4 mg/dL.
On the basis of the CV risk calculated using the 
SCORE scale, three subgroups were extracted. The 
group of medium CV risk (SCORE 1–4%) consisted 
of 376 patients (38.6%). To the group of high CV risk 
(SCORE 5–9%) 369 patients (37.9%) were included. The 
group of very high CV risk (SCORE ≥ 10%) consisted of 
229 patients (23.5%). The results of serum lipid profile 
of the extracted subgroups are presented in Table II.
There was a significantly higher level of LDL-C frac-
tion in the subgroup of very high CV risk in comparison 
to the group of medium and high CV risk (129.4 ± 
± 42.4 vs. 107.7 ± 40.3, p = 0.0001 and 110.7 ± 39.3, 
p = 0.0001, respectively). The level of non-HDL-C was 
also significantly higher in the group with SCORE 
≥ 10 compared to the remaining subgroups of medium 
and high CV risk (respectively, 161.7 ± 47.6 vs. 135.9 ± 
± 46.1 and 137.7 ± 43.1, p = 0.0001). TG level was higher 
in the subgroup of very high CV risk compared to the 
subgroup of high CV risk (167.8 ± 96.4 vs. 134.7 ± 69.0, 
p = 0.0001). There were no statistically significant dif-
ferences in HDL-C levels between the subgroup of very 
high CV risk and the other subgroups. The comparison 
between particular subgroups is shown in Table III. 
Discussion
About 80% of CVD is associated with such behavioural 
risk factors as: unhealthy diet, physical inactivity, to-
bacco use, and harmful use of alcohol. The effects of 
unhealthy diet may show up in individuals as raised 
blood lipids, overweight, and obesity. These factors can 
be easily measured in primary care facilities [2].
In many countries, including Poland, the most 
widespread modifiable risk factors are lipid disorders. 
They occur in more than 60% of Polish adults — about 
18 million people > 18 years old [5, 18]. According to 
the WOBASZ study the frequency of elevated TC is at 
the level of 67% in males and 64% in females, respec-
tively; the elevated LDL-C level is 60% in men and 
55% in women; hypertriglyceridaemia is 32% in males 
and 20% in females, and decreased HDL-C level is 15% 
in men and 17% in women [18]. In the POLSENIOR 
Table II. The results of serum profile in the study group divided into three subgroups according to CV risk (SCORE chart) 
(mean value ± standard deviation [minimum–maximum])
Tabela II. Wyniki zaburzeń lipidowych grupy badanej podzielonej na 3 podgrupy według stwierdzanego ryzyka sercowo- 
-naczyniowego (skala SCORE) (wartość średnia ± odchylenie standardowe [minimum–maksimum])
Parameter Subgroup 1 medium CV risk 
(SCORE 1–4%) (N = 376)
Subgroup 2 high CV risk 
(SCORE 5–9%) (N = 369)
Subgroup 3 very high CV risk 
(SCORE ≥ 10%) (N = 229)
BMI [kg/m2] 30.7 ± 5.77 (18.36–45.77) 30.5 ± 5.6 (18.7–42.8) 30.8 ± 4.3 (18.6–44.6)
LDL-C [mg/dL] 107.7 ± 40.3 (51.0–257) 110.7 ± 39.3 (49.0–231.0) 129.4 ± 42.4 (49.0–266.0)
 HDL-C [mg/dL] 41.5 ± 10.8 (29.0–96.0) 43.8 ± 13.3 (27.0–103.0) 42.5 ± 11.7 (32.0–78.0)
TG [mg/dL] 149.7 ± 100.5 (59.0–542.0) 134.7 ± 69.0 (62.0–476.0) 167.8 ± 96.4 (68.0–489.0)
Non-HDL-C [mg/dL] 135.9 ± 46.1 (48.0–192.0) 137.7 ± 43.1 (45.0–254.0) 161.7 ± 47.6 (48.0–258.0)
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study hypercholesterolaemia was noticed in 62% of 
patients above ≥ 65 years of age (56% in males and 
66% in females) [19]. 
In patients with MetS abdominal obesity is fre-
quently accompanied by lipid metabolism disorders, 
insulin resistance, and elevated blood pressure. In our 
study it occurred in 98% of patients. Abundant evidence 
shows that MetS predicts the development of CVD 
[11–13, 20]. Takahashi showed that individuals with 
MetS have a four-fold greater probability of high CAD 
risk score [3]. Also, the results of other studies indicate 
greater probability for an increase risk of CVD in people 
with MetS [21]. 
Lipid abnormalities probably have an important 
influence on the increase of CV risk. In patients with 
MetS, lipid metabolism disorders also have an unques-
tionable impact on the increase of the risk of CV death. 
In the European Union, the SCORE chart is used 
to estimate CVD risk. The SCORE chart evaluates the 
10-year death risk of cardiovascular disease and is based 
on the following risk factors: gender, age, SBP, TC, and 
smoking. 
According to the most important recommendations 
concerning lipid disorder therapy, published in 2001 
and actualised in 2004 (NCEP-ATP III, National Choles-
terol Educational Program — Adult Treatment Panel), 
to stratify treatment, patients should be divided into 
groups of different risk level according to the SCORE 
scale. Adequate therapeutic goals were designated for 
each group.
It is accordant with guidelines of scientific socie-
ties. According to the ESC/EAS guidelines, TC is rec-
ommended to estimate total CV risk by means of the 
SCORE system [14]. Also, the National Lipid Association 
(NLA) suggest that for the European population the 
SCORE charts should be still recommended. Taking into 
account TC level, the assessment of CV risk in patients, 
especially those with MetS, can be very difficult. Thus, 
for an adequate risk analysis, at least HDL-C and LDL-C 
should be analysed [14].
In our study it was shown that there was a signifi-
cantly higher level of LDL-C fraction in the subgroup 
of very high CV risk in comparison to the group of 
medium and high CV risk (129.4 ± 42.4 vs. 107.7 ± 40.3, 
p = 0.0001 and 110.7 ± 39.3, p = 0.0001, respectively). 
LDL-C, which is calculated using Friedewald’s formula, 
has some limitations. Especially in the case of high TG 
values (> 500 mg/dL) or increased levels of glycaemia 
the LDL-C level can be underestimated. Also, in patients 
with MetS with insulin resistance LDL-C can underes-
timate the LDL particle (LDL-P) number. Despite its 
limitations, the calculated LDL-C is still widely used and 
it is the first lipid target of therapy according to the ESC/ 
/EAS guidelines for the management of dyslipidaemias 
(IA class) [14, 15]. 
Banach et al. [16, 17] also suggest that LDL-C in 
patients with multiple CV risk factors is essential to ef-
fectively manage the overall risk. On the other hand, 
the reviewed published evidence showing a weak and 
potentially misleading association between LDL-C and 
coronary risk in patients with chronic kidney disease 
(CKD) [22]. Furthermore, in the Framingham Offspring 
Study [23] (a Project of the National Heart, Lung, and 
Blood Institute and Boston University) Cromwell WC 
et al. determined that in managing patients at risk 
Table III. Comparison of lipid profile between subgroups 
extracted according to SCORE scale
Tabela III. Porównanie profilu lipidowego w poszczególnych 
podgrupach w zależności od skali SCORE
Parameter (I) SCORE (J) SCORE The difference  
of averages (I-J)
BMI [kg/m2]
1–4%
5–9% .293
≥ 10% –.034
5–9%
1–4% –.293
≥ 10% –.327
≥ 10%
1–4% .034
5–9% .327
LDL–C [mg/dL]
1–4%
5–9% –3.03
≥ 10% –21.73*
5–9%
1–4% 3.03
≥ 10% –18.69*
≥ 10%
1–4% 21.73*
5–9% 18.69*
HDL–C [mg/dL]
1–4%
5–9% –2.36*
≥ 10% –1.04
5–9%
1–4% 2.36*
≥ 10% 1.31
≥ 10%
1–4% 1.04
5–9% –1.31
TG [mg/dL]
1–4%
5–9% 15.01
≥ 10% –18.05
5–9%
1–4% –15.01
≥ 10% –33.06*
≥ 10%
1–4% 18.05
5–9% 33.06*
nonHDL–C [mg/dL]
1–4% 5–9% –1.83
≥ 10% –25.82*
5–9% 1–4% 1.8319
≥ 10% –23.99*
≥ 10% 1–4% 25.82*
5–9% 23.99*
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for CVD to LDL-C target levels, it is unclear whether 
LDL-C provides the optimum measure of residual risk 
and adequacy of LDL-lowering treatment [23]. They 
suggest that LDL-P was a more sensitive indicator of 
low CVD risk than either LDL-C or non-HDL-C, imply-
ing a potential clinical role for LDL-P as a goal of LDL 
management.
Another lipid fraction evaluated in our study was 
TG. A statistically significant higher level of TG was ob-
served in the group of very high CV risk in comparison 
to the group of high CV risk (167.8 ± 96.4 vs. 134.7 ± 
± 69.0, p = 0.0001). Yamamoto et al. suggest that hy-
pertriglyceridaemia may become an independent risk 
factor for atherosclerosis in addition to cholesterol [24]. 
The results of some other studies, published recently, 
also suggest that non-fasting TG may carry informa-
tion regarding remnant lipoproteins associated with 
increased CV risk [2, 25, 26]. It is still debated how this 
should be used in clinical practice. 
The UKPDS identified HDL-C as the second most 
important coronary risk factor, after LDL-C, in patients 
with T2DM [27, 28]. In many patients with MetS athero-
genic dyslipidaemia (AD) (i.e. increased level of TG and 
decreased level of HDL-C) is found. Post hoc analyses of 
prospective trials in stable CHD patients revealed that 
elevated plasma levels of TG and low plasma concentra-
tions of HDL-C are associated with this high risk [29]. 
Plana et al. [30] also determined that AD is an important 
risk factor for CVD. They examined 1137 patients and 
found that AD prevalence was about 27% (34.1% in 
diabetics). They ascertained that when LDL-C levels are 
controlled, AD is more prevalent in patients at highest 
CV risk and with DM [30]. Chapman et al. [31] noticed 
that in many countries AD is on the rise, due to the 
increasing prevalence of MetS, and is more prevalent 
in individuals at high risk of CVD. Interestingly, Her-
mans et al. [32] suggested that log(TG)/HDL-C allows 
for grading of AD and estimating non-LDL-related 
vascular risk in DM females. In the Copenhagen City 
Heart Study, increased risk for myocardial infarction 
(MI), ischaemic stroke, and mortality was evident at 
markedly elevated TG (> 450 mg/dL), although these 
data were not adjusted for non-HDL-C [33]. 
Unfortunately, in our study we did not observe sta-
tistically significant differences between HDL-C levels 
in the subgroup of very high CV risk in comparison 
to the subgroup of moderate and high CV risk [42.5 ± 
± 11.7 vs. 41.5 ± 10.8, p = 0.62 and 43.8 ± 13.3, p = 0.51). 
Wiklund et al. suggested that selected individuals at 
high CV risk HDL-C, Lp(a), and ratios such as LDL-C/ 
/HDL-C or apoB/apoA1 are not recommended as treat-
ment targets [34].
It is worth noting that in our study that non-HDL-C 
levels were significantly different between the group of 
medium and high risk and the group of very high risk 
(135.9 ± 46.1 vs. 161.7 ± 47.6, p = 0.0001, 137.7 ± 43.1 vs. 
161.7 ± 47.6, p = 0.0001, respectively). There was no sig-
nificant difference between the group of medium and 
high CV risk. In epidemiological studies non-HDL-C is 
used as an estimation of the total number of atherogenic 
particles in plasma. Interestingly, non-HDL-C can pro-
vide a better risk estimation compared with LDL-C [35], 
particularly in MetS. The National Cholesterol Educa-
tion Program Adult Treatment Panel III (NCEP ATP III) 
identified non-HDL-C even as the second lipid target 
of therapy after LDL-C [36]. It is also a very important 
target of therapy for CHD prevention [36]. It is easily 
calculated from TC minus HDL-C. Brunzellet et al. sug-
gested that non-HDL-C is a better measure than LDL-C 
for identifying patients at high risk, who had multiple 
CV risk factors [37]. The American Diabetes Association 
(ADA) and the American College of Cardiology (ACC) 
Foundation recommended non-HDL-C goals of <100 
mg/dL for all CHD patients and diabetic patients with 
any other CV risk factor, and a goal of <130 mg/dL 
for all CV metabolic risk patients with two major CV 
risk factors. Also, the NLA endorsed the importance 
of non-HDL-C [38]. Some authors [39,40] suggest that 
it is important to determine whether adding informa-
tion on apoB, apoA1, Lp(a), or lipoprotein-associated 
phospholipase A2 to TC, LDL-C, and HDL-C improves 
CV risk prediction.
Conclusions
In patients with MetS of very high CV risk according to 
the SCORE chart, significantly higher levels of LDL-C, 
TG, and non-HDL-C were observed in comparison to 
the group of high and medium CV risk. Increased CV 
risk in this group of patients may be associated not only 
with higher TC levels, but also the other lipid fractions. 
The results of our study and analysis of the literature 
concerning this topic suggest that assessment of the CV 
risk on the basis of the SCORE chart, which includes 
only the TC level, may be inadequate. Perhaps it is 
worth considering modification of the SCORE chart 
for the European population, to include LDL-C level 
or, in selected cases, non-HDL-C level, instead of TC 
level. Furthermore, in order to assess the CV risk more 
accurately in the groups of very high and high CV risk, 
TG and HDL-C level should be taken into considera-
tion additionally. 
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